Paroxysmal Nocturnal Hemoglobinuria Pipeline Shows Robust Development with 25+ Therapies from Leading Pharmaceutical Companies
Key Insights
DelveInsight (search)'s 2025 pipeline analysis reveals over 20 companies developing 25+ therapies for paroxysmal nocturnal hemoglobinuria (search) (PNH (search)), a rare blood disorder characterized by red blood cell destruction.
Recent regulatory approvals include EMA and FDA approval of PIASKY (crovalimab) from Hoffmann-La Roche for adults and adolescents with PNH (search), marking significant progress in treatment options.
Multiple Phase III trials are underway, including Novartis's positive APPULSE-PNH (search) results for iptacopan and Regeneron's combination therapy study with pozelimab and cemdisiran.
The paroxysmal nocturnal hemoglobinuria (search) (PNH (search)) therapeutic landscape is experiencing unprecedented growth, with more than 20 pharmaceutical companies actively developing over 25 pipeline therapies for this rare blood disorder, according to DelveInsight (search)'s comprehensive 2025 pipeline analysis.
PNH (search) is a rare, acquired blood disorder characterized by premature destruction of red blood cells (hemolysis (search)), blood clotting issues, and potential development of blood clots (thrombosis (search)). The condition arises from mutations in bone marrow stem cells, leading to deficiency or absence of proteins that protect blood cells from immune system attack.
Recent Regulatory Milestones Drive Market Momentum
The PNH (search) treatment landscape achieved significant regulatory success in 2024, with the EMA approving PIASKY (crovalimab) from Hoffmann-La Roche in August for treating adults and adolescents aged 12 and older weighing at least 40 kg with PNH, regardless of prior C5 (search) inhibitor treatment. The US FDA had previously granted approval for PIASKY in June 2024 for adult and pediatric patients aged 13 and older with the same weight requirement.
Crovalimab represents a humanized complement inhibitor C5 (search) monoclonal antibody discovered by Chugai using recycling antibody technology. By blocking the cleavage of C5 to C5a and C5b, it inhibits complement activation, which is the underlying cause of PNH (search) symptoms.
Advanced Clinical Programs Show Promising Results
Novartis reported positive outcomes from the APPULSE-PNH (search) Phase 3B trial in June 2025, evaluating iptacopan (Fabhalta) as a twice-daily oral monotherapy in adults with PNH who had hemoglobin levels of ≥10 g/dL and transitioned from anti-C5 (search) treatments such as eculizumab or ravulizumab. The company announced positive topline results from this multicenter trial in December 2024.
Regeneron Pharmaceuticals initiated a clinical study on August 19, 2025, investigating a novel combination approach with pozelimab and cemdisiran for individuals with PNH (search). The primary objective focuses on assessing long-term safety and efficacy of this combination therapy. Pozelimab is an investigational, fully-human monoclonal antibody designed to block complement factor C5 (search) and prevent red blood cell destruction that causes PNH symptoms.
Innovative Therapeutic Approaches Emerge
The pipeline showcases diverse therapeutic mechanisms beyond traditional complement inhibition. In September 2025, Argo Biopharmaceutical (search) received NMPA approval for a Phase II clinical trial of BW-40202 (search), an investigational siRNA therapy targeting complement factor B (search) (CFB (search)) for PNH (search) treatment, with trials set to begin in January 2026.
NovelMed (search) announced encouraging 12-week interim findings in May 2025 from its ongoing multi-dose Phase II study of Ruxoprubart, an innovative complement-targeting immunotherapy in adults with PNH (search). The interim results demonstrated that Ruxoprubart monotherapy was safe, well-tolerated, and successfully met all primary efficacy goals, leading to transfusion avoidance, higher hemoglobin levels, lower LDH levels, and increased PNH clone size.
Comprehensive Pipeline Spans Multiple Development Stages
Leading companies in the PNH (search) pipeline include Hoffmann-La Roche, AstraZeneca (Alexion Pharmaceuticals), Apellis Pharmaceuticals, Swedish Orphan Biovitrum (search), Regeneron Pharmaceuticals, Alnylam Pharmaceuticals (search), Omeros Corporation, BioCryst Pharmaceuticals, Novartis, and others.
Promising pipeline therapies include SOLIRIS (eculizumab), EMPAVELI/ASPAVELI (pegcetacoplan), Pozelimab (REGN3918), Zaltenibart (OMS906), BCX9930, HRS-5965 tablets, MY008211A tablets, Iptacopan, KP104, NM8074, and Danicopan.
Diverse Therapeutic Modalities and Administration Routes
The pipeline encompasses various molecule types including monoclonal antibodies, peptides, polymers, small molecules, and gene therapy approaches. Route of administration options span oral, parenteral, intravitreal, subretinal, and topical delivery methods, providing flexibility for patient treatment preferences and clinical needs.
Omeros Corporation presented positive Phase 2 clinical data for zaltenibart (OMS906), its investigational MASP-3 (search) inhibitor targeting the alternative complement pathway, at the 66th Annual Meeting of the American Society of Hematology in December 2024. Enrollment for Phase 3 trials in PNH (search) is expected to begin in early 2025.
Market Drivers and Challenges
The rapidly evolving treatment approach for PNH (search), increasing adoption of novel therapeutics, and rising geriatric population are key factors fueling market growth. However, high treatment costs and reimbursement policies present ongoing challenges for market expansion.
The robust pipeline activity reflects the significant unmet medical need in PNH (search) treatment and the pharmaceutical industry's commitment to developing innovative therapeutic solutions for this rare but serious blood disorder.